Zealand Pharma petrelintide hits 10.7% weight loss in Phase 2
Zealand Pharma has published Phase 2 results for petrelintide, its once-weekly amylin analogue, in The Lancet Diabetes and Endocrinology, reporting double-digit weight loss alongside a gastrointestinal tolerability profile that the company says was comparable to placebo. The data were simultaneously presented in an oral session at the 62nd annual meeting of the European Association for the Study of Diabetes (EASD) on 30 September 2026.
The ZUPREME-1 trial was a randomised, double-blind, placebo-controlled, dose-finding study enrolling 485 adults with obesity or overweight with weight-related comorbidities across 32 sites in the United States, Poland, and Romania. Participants received one of five once-weekly subcutaneous doses of petrelintide (1.0 mg, 2.5 mg, 5.0 mg, 7.0 mg or 9.0 mg) or placebo for 42 weeks, including a dose-escalation period.
Trial results
At the maximally effective dose, petrelintide produced a mean body weight reduction of 10.7% from baseline to week 42 compared with 1.7% for placebo on the efficacy estimand. On the treatment policy estimand, the reductions were 10.2% versus 1.4% for placebo. Crucially, gastrointestinal adverse events were generally mild and occurred at rates similar to placebo; at the highest effective dose, there were no reported cases of vomiting and no treatment discontinuations attributable to GI events. This tolerability signal is likely to be a focal point for investors and clinicians, given that nausea and vomiting are persistent complaints with GLP-1 receptor agonists such as semaglutide and tirzepatide.
Beyond weight loss, petrelintide was associated with meaningful improvements in cardiometabolic risk markers. Waist circumference fell by up to 10.8 cm versus 4.3 cm with placebo. High-sensitivity C-reactive protein, a marker of systemic inflammation, was reduced by up to 41% compared with 6% for placebo. Triglycerides fell by up to 21% versus 9%, and pulse rate declined by up to 2.9 beats per minute against a mean increase of 0.3 bpm with placebo. The pulse rate reduction is notable given that GLP-1 agonists are associated with modest heart rate increases.
Market context and competitive positioning
The obesity pharmacotherapy landscape is one of the most intensely contested in drug development. Novo Nordisk's semaglutide and Eli Lilly's tirzepatide have demonstrated weight reductions in the 15–22% range in pivotal trials and are already reshaping prescribing patterns globally. Zealand's case for petrelintide rests on a differentiated mechanism: amylin receptor activation is believed to restore sensitivity to the satiety hormone leptin, working through pathways distinct from incretin-based agents. If the GI tolerability advantage is borne out in Phase 3, it could provide a meaningful differentiator, particularly for patients who discontinue GLP-1 therapy owing to side effects.
Zealand Pharma entered an exclusive collaboration and licensing agreement with Roche in 2025 to co-develop and co-commercialise petrelintide, providing both financing depth and commercial reach as the programme advances. The company has now initiated a three-trial global Phase 3 registrational programme, ZUPREME, with petrelintide monotherapy for chronic weight management. A Phase 2 trial evaluating petrelintide in combination with Zealand's enicepatide was also planned for initiation in the second half of 2026, which could open a combination-therapy pathway targeting both amylin and GLP-1 receptors.
Investors will watch the Phase 3 design closely, particularly the chosen primary endpoint, the comparator arm, and whether the programme is powered to demonstrate superiority or non-inferiority against approved agents. The Lancet publication and the EASD oral presentation mark petrelintide's arrival as a credible late-stage competitor in the crowded but commercially significant weight-management market.